April 29 (Reuters) - Beleaguered Canadian drugmaker Valeant
Pharmaceuticals International Inc VRX.TO filed its annual
report on Friday, which will help it stave of a default on its
$30 billion debt.
The company said it was in compliance with its credit
agreement and senior note indentures.
Valeant said no additional restatements were required beyond
those previously disclosed.